Sutro Biopharma (STRO) — Financial Flexibility Index
Sutro Biopharma (STRO) has a Financial Flexibility Index of -0.13x as of September 2025. Free cash flow of $-37.94 Million (operating CF $-38.19 Million minus capex $251.00K) represents 0% of total liabilities ($296.93 Million). Check Sutro Biopharma strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Sutro Biopharma Financial Flexibility Index (2016–2024)
Historical Financial Flexibility Index trend for Sutro Biopharma across 9 annual periods. See working capital to net assets of Sutro Biopharma to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Sutro Biopharma (2016–2024)
Year-by-year free cash flow to debt coverage for Sutro Biopharma. For the full company profile including market capitalisation, see Sutro Biopharma (STRO) total market value.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.55x | $-188.44 Million | $-191.54 Million | $342.61 Million | ▼ -64.6% |
| 2023 | -0.33x | $-107.30 Million | $-111.62 Million | $321.09 Million | ▼ -656.3% |
| 2022 | 0.06x | $11.41 Million | $3.55 Million | $189.90 Million | ▲ +108.0% |
| 2021 | -0.75x | $-66.36 Million | $-81.68 Million | $88.84 Million | ▲ +23.6% |
| 2020 | -0.98x | $-60.67 Million | $-67.80 Million | $62.06 Million | ▲ +6.9% |
| 2019 | -1.05x | $-61.54 Million | $-65.02 Million | $58.58 Million | ▼ -775.8% |
| 2018 | 0.16x | $14.24 Million | $12.68 Million | $91.60 Million | ▲ +169.0% |
| 2017 | -0.23x | $-33.76 Million | $-37.07 Million | $149.77 Million | ▼ -312.2% |
| 2016 | -0.05x | $-8.76 Million | $-13.15 Million | $160.18 Million | — |